•
Mar 31, 2023

Akoya Q1 2023 Earnings Report

Akoya reported record revenue and instrument placements in Q1 2023.

Key Takeaways

Akoya Biosciences reported a strong start to 2023 with record quarterly revenue of $21.4 million, representing a 27% year-over-year growth. The company also achieved a milestone of 1000 spatial instrument placements in April. Akoya is reiterating its full-year 2023 revenue guidance range of $95-98 million.

Total revenue reached $21.4 million, a 26.6% increase compared to the prior year period.

Product revenue increased by 16.5% to $15.5 million, with instrument revenue up 12.9% and reagent revenue up 23.9%.

Service and other revenue increased significantly by 63.9% to $5.9 million.

The company sold 58 instruments and had an installed base of 992 instruments as of March 31, 2023.

Total Revenue
$21.4M
Previous year: $16.9M
+26.7%
EPS
-$0.49
Previous year: -$0.44
+11.4%
Gross Profit
$12.3M
Previous year: $10.1M
+21.8%
Cash and Equivalents
$60.2M
Previous year: $93.9M
-35.9%
Free Cash Flow
-$20.6M
Previous year: -$19.1M
+7.8%
Total Assets
$154M
Previous year: $187M
-17.5%

Akoya

Akoya

Akoya Revenue by Segment

Forward Guidance

Akoya continues to expect a full year 2023 revenue guidance range of $95-98 million.